Shares of Apnimed are set to make their trading debut Friday after the clinical-stage pharmaceutical company's upsized initial public offering was priced at the high end of expectations, raising $192 million.
Apnimed late Thursday said it is selling 12 million shares at $16 each in the IPO, compared with prior plans to offer 10 million shares at between $14 and $16 apiece.
Apnimed shares are due to begin trading later Friday on the Nasdaq Global Select Market under the symbol APMD.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.